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Psychometric validation 
of the needs assessment 
tool: progressive disease in 
interstitial lung disease
ABSTRACT 
The inter-rater/test–retest reliability and 
construct validity of a palliative care needs 
assessment tool in interstitial lung disease 
(NAT:PD-ILD) were tested using NAT:PD-
ILD-guided video-recorded consultations, 
and NAT:PD-ILD-guided consultations, 
and patient and carer-report outcomes (St 
George’s Respiratory Questionnaire (SGRQ)-
ILD, Carer Strain Index (CSI)/Carer Support 
Needs Assessment Tool (CSNAT)). 11/16 items 
reached at least fair inter-rater agreement; 
5 items reached at least moderate test–
retest agreement. 4/6 patient constructs 
demonstrated agreement with SGRQ-I scores 
(Kendall’s tau-b, 0.24–20.36; P<0.05). 4/7 
carer constructs agreed with the CSI/CSNAT 
items (kappa, 0.23–20.53). The NAT:PD-ILD 
is reliable and valid. Clinical effectiveness and 
implementation are to be evaluated.
InTRoduCTIon
People with interstitial lung disease (ILD) 
are symptomatic,1 and have limited 
disease-modifying treatment options, poor 
prognosis and poor quality of life.2 Iden-
tification and management of patients’ 
and carers’ palliative care needs are rare 
despite policy directives promoting palli-
ative care,3 and availability of palliative 
interventions.4 
The validated needs assessment tool 
in cancer (NAT:PD-C) helps clinicians 
identify and address palliative needs in 
daily practice.5 We adapted, validated and 
tested the reliability of the NAT:PD-C 
for patients with ILD (NAT:PD-ILD) 
and explored implementation implica-
tions in practice. This single page guide 
prompts clinicians to assess holistic needs 
(priority prompts for specialised palliative 
care input, patients’ well-being, informal 
carers’ needs and information needs), 
triage ongoing care (‘directly managed’, 
‘refer to other team member’, ‘refer to 
specialist palliative care’) and also acts as 
a referral form.
MeThodS
Summary design
The initial adaptation, face and content 
validation6 and implementation work7 
are reported elsewhere. This study tested 
the psychometric properties of (1) inter-
rater and test–retest reliability, and (2) 
construct validity. 
Clinicians (doctors, nurses, physiother-
apists), patients with ILD and their family 
carers were recruited from four ILD 
tertiary referral clinics.
Inter-rater and test–retest reliability
Video recordings were made of 10 
patient-clinician consultations (range of 
disease severity and carer present/absent, 
with clinicians using the NAT:PD-ILD 
to guide assessment). Clinicians were 
trained to use the NAT:PD-ILD and 
rated at least one video consultation 
(group viewing or individual viewing 
via secure online service). Clinicians 
were asked to rerate the same video 
at least 2 weeks later. Weighted Fleiss’ 
kappa with quadratic weights was calcu-
lated for the ratings on 10 videos (kappa 
<0=poor agreement, 0–0.20=slight, 
0.21–0.40=fair, 0.41–0.60=moderate, 
0.61–0.80=substantial, 0.81–
1=almost perfect agreement).8 Data 
simulations indicated that we required 60 
paired assessment ratings to detect at least 
‘substantial’ inter-rater agreement (kappa 
>0.6) for the item 4 (‘Is the patient expe-
riencing unresolved physical symptoms?’) 
with 80% power.
Construct validation
Trained clinicians conducted a NAT:PD-
ILD-guided clinic consultation. Patients 
completed the St George’s Respiratory 
Questionnaire (SGRQ-I) and carers 
completed the Carer Strain Index (CSI) 
and Carer Support Needs Assessment Tool 
(CSNAT). Kendall’s tau-b correlation 
coefficient was calculated to determine 
the correlation between the NAT:PD-ILD 
patient well-being items and a subset of 
SGRQ-I similar constructs identified a 
priori. The prevalence and bias-adjusted 
kappa (PABAK), Cohen’s kappa and 
observed percentage agreement were 
used to assess agreement between the 
NAT:PD-ILD carer items and appropriate 
CSI and CSNAT constructs identified a 
priori. Data simulations indicated that a 
sample size of 65 patients would allow 
estimation of the kappa statistic for agree-
ment such that the CI would not extend 
beyond the neighbouring category.
All analyses were conducted using Stata 
V.13 (StataCorp, Stata Statistical Soft-
ware: Release 13. College Station, TX: 
StataCorp, 2013).
ReSulTS
Reliability
Fifty-three clinicians (32 doctors, 18 phys-
iotherapists, 2 clinical physiologists, 1 
nurse) participated in 64 first views across 
10 videos, with 21 test–retest observations 
on four videos.
Inter-rater reliability
Eleven (69%) NAT:PD-ILD items 
reached at least fair agreement (weighted 
kappa >0.2).
Test–retest reliability
Five items exhibited at least moderate 
agreement (weighted kappa >0.4) 
(table 1).
Construct validation
Nine clinicians (six doctors, three nurses) 
and 68 patients (mean age 66, SD 10.3; 
62% men; 45 with a carer (28 partici-
pated); 35% oxygen therapy; 56% inter-
stital pulmonary fibrosis ; 80% Medical 
Research Council breathlessness 3–5) were 
recruited (online supplementary eTable 
1). The SGRQ-I mean summary score 
was 62.5 (SD 20.9): symptom component 
67.4 (26.1); activities component 82.1 
(23.2); impact component 51.2 (24.3). 
Scores for the carer comparator outcome 
measures are shown in online supple-
mentary eTable 2. Agreement between 
NAT:PD-ILD concerns and comparator 
outcomes is shown in table 2. Items 2 
(unresolved psychological symptoms/
loss quality of life), 3 (problems with daily 
living activities), 5 (work, financial or legal 
concerns) and 6 (health beliefs, cultural 
or social factors) of the NAT:PD-ILD 
were significantly positively correlated 
with their comparator SGRQ-I scores (r 
range 0.24–0.36, P<0.05). PABAK values 
comparing the NAT:PD-ILD items with 
CSI/CSNAT items were mostly positive 
(0.04–0.57, minimum 52% agreement); 
however, items 11 and 13 have negative 
PABAK values (interpersonal relationships 
and grief topics).
dISCuSSIon
Items within the NAT:PD-ILD demon-
strated acceptable inter-rater reliability 
and construct validation given the broad 
constructs assessed and the breadth of 
clinical experience. The constructs of 
patient-reported quality of life (SGRQ-I) 
and assessment of need are related but 
different, therefore the relatively small 
number of items rated as moderate or 
strong is unsurprising. Similarly, many 
carer-related items both on NAT:PD-ILD 
and within CSI and CSNAT capture 
areas of concern that overlap, but are not 
directly comparable. The NAT-PD-C, with 
similar psychometric properties, resulted 
in reduced patient and carer needs when 
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applied in practice; the key factor in any 
clinical tool.5
The NAT:PD-ILD is best seen as a 
communication and decision tool where 
action is thereby triggered if more 
in-depth exploration is needed, rather 
than an outcome measurement. The 
challenges of a clinical assessment and 
diagnosis are recognised as an inexact 
science with variation between clini-
cians.9 10 Study clinicians had a wide 
range of clinical experience to increase 
generalisability. Some NAT:PD-ILD 
items with poor agreement (inter-rater 
and construct) are consistent with the 
clinician participants’ expressed lack of 
confidence, for example, spiritual and 
existential concerns and may rather 
reflect an educational need.7
The clinician participants rated the 
videos after 10–15 min of training, inter-
rater reliability is likely to improve with 
practice. Clinicians using the tool in daily 
practice will gain more experience as they 
use the tool.
Although we reached our target sample 
size for the construct validity analysis, 
we have insufficient sample for the 
carer comparisons. Also, our sample was 
convenience, not consecutive, potentially 
affecting representativeness.
The tool is yet to be tested in a clin-
ical trial to evaluate its use by clinicians 
in terms of impact on patient and carer 
experience.
ConCluSIonS
The adapted NAT:PD-ILD has adequate 
reliability and construct validation. Effec-
tiveness in clinical practice, and optimum 
implementation are yet to be evaluated 
and identified.
Miriam J Johnson,1 Armita Jamali,2 Joy Ross,3 
Caroline Fairhurst,4 Jason Boland,1 
Carla Reigada,5 Simon Paul hart,5 Gunn Grande,6 
david C Currow,1,7 Athol u Wells,8 
Sabrina Bajwah,9 Thanos Papadopoulos,10 
J Martin Bland,4 Janelle Yorke6
1Wolfson Palliative Care Research Centre, Hull York 
Medical School, University of Hull, Hull, UK
2Specialist Trainee in Palliative Medicine, Pembridge 
Palliative Care Unit, London, UK
3St Christopher’s Hospice, London, UK
4Department of Health Sciences, University of York, 
York, UK
5Hull York Medical School, University of Hull, Hull, UK
6Division of Nursing, Midwifery and Social Work, 
University of Manchester and The Christie NHS 
Foundation Trust, Manchester, UK
7Faculty of Heath, University of Technology Sydney, 
IMPACCT, Sydney, New South Wales, Australia
8Respiratory Medicine, Royal Brompton and Harefield 
NHS Trust, London, UK
9Cicely Saunders Institute, Kings College London, 
London, UK
10Kent Business School, University of Kent, Kent, UK
Correspondence to Professor Miriam J Johnson, 
Hertford Building, Hull York Medical School, University 
of Hull, Hull HU6 7RX, UK;  miriam. johnson@ hyms. ac. uk
Acknowledgements We would like to thank the 
patients, carers and clinicians who took part in this 
study for their time and insights. The tool is available 
through the NICE.
Contributors MJJ and DC conceived the study and 
design. MJJ, DCC, MB, JMB, JR, JY, GG and TP. MJJ, 
DCC and JY wrote the protocol. JR, AJ and JA led on 
reliability testing. JY led on construct. GG provided 
carer assessment expertise. JMB and CF conducted 
the analysis. All authors contributed to interpretation. 
MJJ wrote the first draft and all authors contributed to 
revisions and the final draft.
Funding This work was supported bythe Marie Curie 
Research Grants Scheme, grant (MCCC-RP-14-A16976)
Competing interests None declared.
ethics approval National Research Ethics Service 
North East-Tyne & Wear South (14/NE/0127) and 
institutional approval was obtained.
Provenance and peer review Not commissioned; 
externally peer reviewed.
data sharing statement The corresponding author 
can be contacted regarding use of anonymised data.
open Access This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build 
upon this work non-commercially, and license their 
derivative works on different terms, provided the 
original work is properly cited and the use is non-
commercial. See: http:// creativecommons. org/ licenses/ 
by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless 
otherwise stated in the text of the article) 2017. All 
rights reserved. No commercial use is permitted unless 
otherwise expressly granted.
 ► Additional material is published online only. To 
view please visit the journal online (http:// dx. doi. org/ 
10. 1136/ thoraxjnl- 2017- 210911)
To cite Johnson MJ, Jamali A, Ross J, et al. Thorax 
Published Online First: [please include Day Month Year]. 
doi:10.1136/thoraxjnl-2017-210911
Received 14 August 2017
Revised 20 October 2017
Accepted 6 November 2017
Thorax 2017;0:1–4.
doi:10.1136/thoraxjnl-2017-210911
ReFeRenCeS
 1 Byrne A, Sampson C, Baillie J, et al. A mixed-methods 
study of the care needs of individuals with idiopathic 
pulmonary fibrosis and their carers--CaNoPy: a study 
protocol. BMJ Open 2013;3:e003537.
 2 Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-
related quality of life in patients with idiopathic 
pulmonary fibrosis: a systematic review. Thorax 
2005;60:588–94.
 3 National Institute for Health and Care Excellence. 
Idiopathic pulmonary fibrosis. Quality statement 
5: palliative care, 2015. https://www. nice. org. uk/ 
guidance/ qs79/ chapter/ Quality- statement- 5- Palliative- 
care.
 4 Bajwah S, Ross JR, Peacock JL, et al. Interventions to 
improve symptoms and quality of life of patients with 
fibrotic interstitial lung disease: a systematic review of 
the literature. Thorax 2013;68:867–79.
 5 Waller A, Girgis A, Johnson C, et al. Improving 
outcomes for people with progressive cancer: 
interrupted time series trial of a needs 
assessment intervention. J Pain Symptom Manage 
2012;43:569–81.
 6 Boland JW, Reigada C, Yorke J, et al. The adaptation, 
face, and content validation of a needs assessment 
tool: progressive disease for people with interstitial 
lung disease. J Palliat Med 2016;19:549–55.
 7 Reigada C, Papadopoulos A, Boland JW, et al. 
Implementation of the Needs Assessment Tool for 
patients with interstitial lung disease (NAT:ILD): 
facilitators and barriers. Thorax 2017;72:1049–51.
 8 Landis JR, Koch GG. The measurement of observer 
agreement for categorical data. Biometrics 
1977;33:159–74.
 9 Joshua AM, Celermajer DS, Stockler MR. Beauty 
is in the eye of the examiner: reaching agreement 
about physical signs and their value. Intern Med J 
2005;35:178–87.
 10 Shinar D, Gross CR, Mohr JP, et al. Interobserver 
variability in the assessment of neurologic history and 
examination in the Stroke Data Bank. Arch Neurol 
1985;42:557–65.
group.bmj.com on December 12, 2017 - Published by http://thorax.bmj.com/Downloaded from 
interstitial lung disease
assessment tool: progressive disease in 
Psychometric validation of the needs
and Janelle Yorke
Athol U Wells, Sabrina Bajwah, Thanos Papadopoulos, J Martin Bland
Boland, Carla Reigada, Simon Paul Hart, Gunn Grande, David C Currow, 
Miriam J Johnson, Armita Jamali, Joy Ross, Caroline Fairhurst, Jason
 published online November 17, 2017Thorax 
 1
http://thorax.bmj.com/content/early/2017/11/17/thoraxjnl-2017-21091
Updated information and services can be found at: 
These include:
References
 #BIBL1
http://thorax.bmj.com/content/early/2017/11/17/thoraxjnl-2017-21091
This article cites 9 articles, 4 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (270)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on December 12, 2017 - Published by http://thorax.bmj.com/Downloaded from 
